Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants.

Publication Type:

Journal Article


Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 17, Issue 18, p.5913-25 (2011)


2011, Alternative Splicing, androgens, Androstenols, Animals, Biosynthetic Pathways, Cell Proliferation, Center-Authored Paper, Clinical Research Division, DIHYDROTESTOSTERONE, Disease Models, Animal, Drug Resistance, Neoplasm, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Human Biology Division, Humans, Male, MICE, Mice, SCID, Prostatic Neoplasms, Receptors, Androgen, September 2011, Steroid 17-alpha-Hydroxylase, Xenograft Model Antitumor Assays


Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and suppresses tumor growth in patients with castration-resistant prostate cancer (CRPC). The effectiveness of abiraterone in reducing tumor androgens is not known, nor have mechanisms contributing to abiraterone resistance been established.